TargetMol

Omeprazole

Product Code:
 
TAR-T0757
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0757-50mg50mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0757-100mg100mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0757-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0757-200mg200mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0757-500mg500mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Omeprazole is a proton pump inhibitor (PPI), Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
CAS:
73590-58-6
Formula:
C17H19N3O3S
Molecular Weight:
345.42
Pathway:
Microbiology/Virology; Metabolism; Membrane transporter/Ion channel; Autophagy
Purity:
0.9959
SMILES:
COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C
Target:
Proton pump; Phospholipase; Antibacterial; Autophagy

References

1. Dzeletovic N, et al. J Biol Chem, 1997, 272(19), 12705-12713. 2. Scaringi L, et al. Scand J Immunol, 1996, 44(3), 204-214. 3. Hyun JJ, et al. Int J Mol Med, 2010, 26(6), 877-883. 4. Karam SM, et al. Am J Physiol, 1994, 266(4 Pt 1), G745-758. 5. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating na?ve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297.